Outcomes following mepolizumab treatment discontinuation: real-world experience from an open-label trial

Outcomes following mepolizumab treatment discontinuation: real-world experience from an open-label trial

Abstract Limited information is available on the clinical course of patients with severe asthma following discontinuation of biologic treatment. Therefore, a post hoc analysis was conducted in patients with severe eosinophilic asthma who participated in the COSMOS trial, where patients received mepo...

Full description

Bibliographic Details
Main Authors: Hector Ortega, Catherine Lemiere, Jean-Pierre Llanos, Mark Forshag, Robert Price, Frank Albers, Steven Yancey, Mario Castro
Format: Article
Language:English
Published: BMC 2019-06-01
Series:Allergy, Asthma & Clinical Immunology
Subjects:
Severe eosinophilic asthma
Cessation of treatment
Asthma control
Blood eosinophils
Online Access:http://link.springer.com/article/10.1186/s13223-019-0348-z

Internet

http://link.springer.com/article/10.1186/s13223-019-0348-z

Similar Items